Ad

HEM – Hemostemix Inc

Compliant

★★★☆☆

Hemostemix Inc is Shariah compliant. The company’s financials pass three standards and fail in two.

$19,167,676

Market cap

-

Revenue Growth

-

Analysts' Rating

Ad
N/A

1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL

Total Analysts: 0

Company Profile

Hemostemix Inc. is a Canada-based clinical stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies for medical conditions. The Company’s lead product candidate, Angiogenic Cellular Precursor (ACP-01), is an autologous cell therapy to treat critical limb ischemia (CLI) in patients who are facing amputation. ACP-01 is in phase II clinical trial for CLI. The Company also focuses on developing other cell products, such as Neural Cellular Precursor (NCP-01) and Bone Cellular Precursor (BCP-01). It focuses to use NCP-01 for the treatment of Amyotrophic lateral sclerosis (ALS), Alzheimer’s, and Parkinson’s disease. BCP-01 is a product candidate to treat indications, such as bone fractures, skeletal breaks, and surgical procedures. The Company’s wholly owned subsidiaries include Kwalata Trading Limited and Hemostemix Ltd.

We do our best to screen stocks as accurately as possible. Please let us know in the comments if you spot an error or find something questionable. Jazaak Allahu khairan

Ad

Responses